JP2002502885A - 増強された遺伝子送達のための、核酸および血管作用性薬剤の組合せ - Google Patents

増強された遺伝子送達のための、核酸および血管作用性薬剤の組合せ

Info

Publication number
JP2002502885A
JP2002502885A JP2000531196A JP2000531196A JP2002502885A JP 2002502885 A JP2002502885 A JP 2002502885A JP 2000531196 A JP2000531196 A JP 2000531196A JP 2000531196 A JP2000531196 A JP 2000531196A JP 2002502885 A JP2002502885 A JP 2002502885A
Authority
JP
Japan
Prior art keywords
vector
histamine
fgf
protein
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000531196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002502885A5 (https=
Inventor
エイチ． カーク ハモンド，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2002502885A publication Critical patent/JP2002502885A/ja
Publication of JP2002502885A5 publication Critical patent/JP2002502885A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Paints Or Removers (AREA)
JP2000531196A 1998-02-11 1999-02-09 増強された遺伝子送達のための、核酸および血管作用性薬剤の組合せ Pending JP2002502885A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2177398A 1998-02-11 1998-02-11
US09/021,773 1998-02-11
PCT/US1999/002702 WO1999040945A2 (en) 1998-02-11 1999-02-09 Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery

Publications (2)

Publication Number Publication Date
JP2002502885A true JP2002502885A (ja) 2002-01-29
JP2002502885A5 JP2002502885A5 (https=) 2006-03-30

Family

ID=21806073

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000531196A Pending JP2002502885A (ja) 1998-02-11 1999-02-09 増強された遺伝子送達のための、核酸および血管作用性薬剤の組合せ

Country Status (11)

Country Link
EP (2) EP1695719A1 (https=)
JP (1) JP2002502885A (https=)
KR (1) KR20010015915A (https=)
CN (2) CN101186928A (https=)
AU (1) AU2663799A (https=)
CA (1) CA2320302A1 (https=)
EA (1) EA019099B1 (https=)
IL (1) IL137765A0 (https=)
NZ (1) NZ545047A (https=)
WO (1) WO1999040945A2 (https=)
ZA (1) ZA991102B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544698A (ja) * 2006-07-25 2009-12-17 セラドン・コーポレーション 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034208A1 (en) * 1999-11-05 2001-05-17 The Regents Of The University Of California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
WO2000024415A2 (en) 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
EP1255822A2 (en) 1999-12-27 2002-11-13 The Regents Of The University Of California Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure
WO2002002148A2 (en) * 2000-06-30 2002-01-10 Collateral Therapeutics, Inc. Dual recombinant gene therapy compositions and methods of use
JP2005052001A (ja) * 2001-07-05 2005-03-03 Takara Bio Inc 遺伝子治療剤
DE602006017071D1 (de) 2005-01-25 2010-11-04 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
US8157760B2 (en) 2007-07-18 2012-04-17 Silk Road Medical, Inc. Methods and systems for establishing retrograde carotid arterial blood flow
WO2009105135A1 (en) 2008-02-19 2009-08-27 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
US20130096500A1 (en) * 2011-07-07 2013-04-18 Gabor Rubanyi Nucleic acid based cardiovascular therapeutics
US20140296769A1 (en) * 2013-03-28 2014-10-02 Silk Road Medical, Inc. Methods and Systems for Establishing Retrograde Carotid Arterial Blood Flow
WO2019089385A1 (en) 2017-11-02 2019-05-09 Silk Road Medical, Inc. Fenestrated sheath for embolic protection during transcarotid carotid artery revascularization

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA001616B1 (ru) * 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
US5869230A (en) * 1995-03-30 1999-02-09 Beth Israel Hospital Association Gene transfer into the kidney
WO1999017807A1 (en) * 1997-10-08 1999-04-15 Cobra Therapeutics Ltd. Use of a vasoactive compound in the enhancement of gene delivery
US6376471B1 (en) * 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544698A (ja) * 2006-07-25 2009-12-17 セラドン・コーポレーション 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入
JP2014218509A (ja) * 2006-07-25 2014-11-20 セラドン・コーポレーション 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入

Also Published As

Publication number Publication date
CN1301181A (zh) 2001-06-27
ZA991102B (en) 2000-03-31
EA200000828A1 (ru) 2001-02-26
WO1999040945A3 (en) 1999-09-30
AU2663799A (en) 1999-08-30
CN101186928A (zh) 2008-05-28
NZ545047A (en) 2009-05-31
EP1695719A1 (en) 2006-08-30
CN100350979C (zh) 2007-11-28
IL137765A0 (en) 2001-10-31
KR20010015915A (ko) 2001-02-26
EA019099B1 (ru) 2014-01-30
WO1999040945A2 (en) 1999-08-19
CA2320302A1 (en) 1999-08-19
EP1053025A2 (en) 2000-11-22

Similar Documents

Publication Publication Date Title
JP3961019B2 (ja) 遺伝子転移媒介の血管形成療法
US5792453A (en) Gene transfer-mediated angiogenesis therapy
US20090082293A1 (en) Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
AU784392B2 (en) Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
CA2289600C (en) Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
JP2002502885A (ja) 増強された遺伝子送達のための、核酸および血管作用性薬剤の組合せ
AU2006200170B2 (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
AU706050C (en) Gene transfer-mediated angiogenesis therapy
HK1094944A (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
AU2006235836A1 (en) Gene transfer-mediated angiogenesis therapy
AU4754199A (en) Gene transfer-mediated angiogenesis therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090612

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090623

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091118